natgillin/translations-raw huggingface dataset:
In healthy young men, an oral 3 mg dose decreases acetylcholinesterase (AChE) activity in CSF by approximately 40 % within the first 1.5 hours after administration.
Pri zdravih mladih moških peroralni 3-miligramski odmerek zmanjša aktivnost acetilholinesteraze (AChE) v cerebrospinalni tekočini za približno 40 % prve 1,5 uri po uporabi.
In hepatic transplant patients initiated on mycophenolate mofetil and tacrolimus, the AUC and Cmax of MPA, the active metabolite of mycophenolate mofetil, were not significantly affected by co- administration with tacrolimus.
Pri bolnikih z jetrnim presadkom, pri katerih so uvedli mofetilmikofenolat in takrolimus, sprememba AUC in cmax mikofenolne kisline, aktivnega presnovka mofetilmikofenolata, zaradi sočasnega dajanja takrolimusa ni bila pomembna.
In hepatically impaired patients, it is recommended that sirolimus whole blood trough levels be closely monitored.
Pri bolnikih z jetrno okvaro priporočamo skrbno spremljanje najnižje koncentracije sirolimusa v stanju dinamičnega ravnovesja v polni krvi.
In hidradenitis suppurativa, 59% of patients receiving Humira in one main study and 42% of patients in another achieved at least a 50% reduction in abscesses and nodules after 12 weeks, without any increase in abscess count or fistulas.
Pri hidradenitis suppurativi je v eni glavni študiji pri 59 % bolnikov, ki so prejemali zdravilo Humira, in v drugi pri 42 %, po 12 tednih prišlo do vsaj 50-odstotnega zmanjšanja abscesov in nodulov, ne da bi se povečalo število abscesov ali fistul.
In hip fracture patients, associated with their increased age, fondaparinux steady state plasma concentrations are: Cmax (mg/l) - 0.50 (32%), Cmin (mg/l) - 0.19 (58%).
Pri bolnikih z zlomom kolka, povezanim z njihovo višjo starostjo, so plazemske koncentracije fondaparinuksa v stanju dinamičnega ravnovesja: Cmax (mg/l) – 0,50 (32 %), Cmin (mg/l) – 0,19 (58
In hip fracture patients, associated with their increased age, fondaparinux steady state plasma concentrations are: Cmax (mg/l) - 0.50 (32%), Cmin (mg/l) - 0.19 (58%).
Pri bolnikih z zlomom kolka, povezanim z njihovo višjo starostjo, so plazemske koncentracije fondaparinuksa v stanju dinamičnega ravnovesja: Cmax (mg/l) – 0,50 (32 %), Cmin (mg/l) – 0,19 (58 %).
In hip replacement surgery, the first study compared five weeks of Xarelto with five weeks of enoxaparin in around 4,500 patients, and the second study compared five weeks of Xarelto with two weeks of enoxaparin in around 2,500 patients.
Pri kirurški zamenjavi kolka so v prvi študiji pri okoli 4 500 bolnikih pettedensko jemanje zdravila Xarelto primerjali s pettedenskim jemanjem enoksaparina, v drugi študiji pa so pri okoli 2 500 bolnikih pettedensko jemanje zdravila Xarelto primerjali z dvotedenskim jemanjem enoksaparina.
In HIV infected patients co-infected with HBV, clinical and laboratory evidence of hepatitis have occurred after discontinuation of tenofovir disoproxil fumarate (see section 4.4).
Pri bolnikih s HIV, sočasno okuženih s HBV, so po prekinitvi zdravljenja z dizoproksiltenofovirijevim fumaratom opazili klinične in laboratorijske znake hepatitisa (glejte poglavje 4.4).
In HIV infected patients co-infected with HBV, clinical and laboratory evidence of hepatitis have occurred after discontinuation of treatment (see section 4.4).
Pri bolnikih, okuženih z virusom HIV, ki imajo hkratno okužbo z virusom HBV, so se po prekinitvi zdravljenja pokazali klinični in laboratorijski znaki hepatitisa (glejte poglavje 4.4).
In HIV infected patients treated with CART, including with emtricitabine, immune reactivation syndrome has been reported.
Pri s HIV okuženih bolnikih, zdravljenih s CART, vključno z emtricitabinom, so poročali o sindromu imunske reaktivacije.
In HIV infected patients with severe immune deficiency at the time of initiation of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic infections may arise.
Pri bolnikih, okuženih s HIV, ki imajo hudo imunsko pomanjkljivost v času uvedbe kombinirane protiretrovirusne terapije (CART), se lahko pojavi vnetna reakcija na asimptomatske ali prikrite oportunistične okužbe .
In HIV infected patients, in a 144-week controlled clinical study that compared tenofovir disoproxil fumarate with stavudine in combination with lamivudine and efavirenz in antiretroviral-naïve adult patients, small decreases in bone mineral density (BMD) of the hip and spine were observed in both treatment groups.
V 144 tednov trajajoči kontrolirani klinični študiji, v kateri sta bila primerjana dizoproksiltenofovirijev fumarat in stavudin v kombinaciji z lamivudinom in efavirenzom pri odraslih bolnikih, okuženih z virusom HIV, ki še niso bili zdravljeni s protiretrovirusnimi zdravili, so pri obeh zdravljenih skupinah opazili manjše zmanjšanje mineralne gostote kosti (MGK) kolka in hrbtenice.
in HIV patients enlargement of the spleen (splenomegaly)
pri bolnikih s HIV povečanje vranice (splenomegalija)
in HIV patients enlargement of the spleen (splenomegaly)
pri bolnikih, okuženih s HIV povečanje vranice (splenomegalija)
in HIV patients enlargement of the spleen (splenomegaly)
pri bolnikih, okuženih z virusom HIV povečanje vranice (splenomegalija)
in HIV patients pain in your muscles or bones (musculoskeletal pain)
pri bolnikih s HIV bolečine v mišicah ali kosteh (mišično-skeletne bolečine)
in HIV patients pain in your muscles or bones (musculoskeletal pain)
pri bolnikih, okuženih s HIV bolečine v mišicah ali kosteh (mišično-skeletne bolečine)
in HIV patients pain in your muscles or bones (musculoskeletal pain)
pri bolnikih, okuženih z virusom HIV bolečine v mišicah in kosteh (mišično-skeletne bolečine)
in HIV patients severe pain in the bones, chest, gut or joints (sickle cell crisis)
pri bolnikih s HIV hude bolečine v kosteh, prsih, trebuhu ali sklepih (srpastocelična kriza)
in HIV patients severe pain in the bones, chest, gut or joints (sickle cell crisis)
pri bolnikih s HIV hude bolečine v kosteh, prsnem košu, črevesju ali sklepih (srpastocelična kriza)
in HIV patients severe pain in the bones, chest, gut or joints (sickle cell crisis)
pri bolnikih, okuženih s HIV hude bolečine v kosteh, prsnem košu, prebavilih ali sklepih (srpastocelična kriza)
In HIV Viread should always be used combined with other medicines to treat HIV infection.
Zdravilo Viread je treba vedno uporabljati v kombinaciji z drugimi zdravili za zdravljenje okužbe z virusom HIV.
In HIV-1 infected adolescents, the BMD Z-scores observed in subjects who received tenofovir disoproxil fumarate were lower than those observed in subjects who received placebo.
Pri mladostnikih, okuženih s HIV-1, so pri osebah, ki so prejemale dizoproksiltenofovirijev fumarat, opazili nižji Z-indeks MGK kot pri osebah, ki so prejemale placebo.
In HIV-1 infected children, the BMD Z-scores observed in subjects who switched to tenofovir disoproxil fumarate were lower than those observed in subjects who remained on their stavudine- or zidovudine-containing regimen (see sections 4.4 and 5.1).
Pri otrocih, okuženih s HIV-1, so pri osebah, ki so prešle na dizoproksiltenofovirijev fumarat, opazili nižji Z-indeks MGK kot pri osebah, ki so ostale na režimu zdravljenja, ki je vseboval stavudin ali zidovudin (glejte poglavji 4.4 in 5.1).
In HIV-1 infected patients with renal risk factors, the co-administration of tenofovir disoproxil fumarate with a boosted protease inhibitor should be carefully evaluated.
Pri bolnikih s HIV–1 z dejavniki tveganja za okvaro ledvic je treba sočasno uporabo dizoproksiltenofovirijevega fumarata z okrepljenimi zaviralci proteaze skrbno pretehtati.
In HIV-1 infected patients with renal risk factors, the co-administration of tenofovir disoproxil with a boosted protease inhibitor should be carefully evaluated.
Pri bolnikih s HIV–1 z dejavniki tveganja za okvaro ledvic je treba sočasno uporabo dizoproksiltenofovirijevega fumarata z okrepljenimi zaviralci proteaze skrbno pretehtati.
In HIV-HCV co-infected patients, the clinical adverse reaction profiles reported for Pegasys, alone or in combination with ribavirin, were similar to those observed in HCV mono-infected patients For
Klinični profili neželenih učinkov za zdravilo Pegasys ali kombinacijo zdravila Pegasys z ribavirinom, ki so jih opazili pri bolnikih, sočasno okuženih s HIV in HCV, so bili podobni kot pri bolnikih, okuženih le s HCV.
In HIV-infected adults, adding Viread to existing treatment resulted in a fall in viral load of around 75% after four and after 24 weeks, compared with a small rise or fall in viral load of around 5% in the patients taking placebo.
Pri odraslih, okuženih z virusom HIV, je bilo z dodajanjem zdravila Viread obstoječemu zdravljenju doseženo približno 75-odstotno zmanjšanje virusnega bremena po štirih in 24 tednih v primerjavi z manjšim povečanjem ali zmanjšanjem virusnega bremena za okrog 5 % pri bolnikih, ki so prejemali placebo.
In HIV-infected patients with atazanavir/ritonavir at an increased dose of 400/100 mg once daily
Pri z virusom HIV okuženih bolnikih, ki so se zdravili z atazanavirjem/ritonavirjem v zvišanem odmerku 400/100 mg enkrat na dan
In HIV-infected patients with atazanavir/ritonavir at the recommended dose 300/100 mg once daily
Pri z virusom HIV okuženih bolnikih, ki so se zdravili z atazanavirjem/ritonavirjem v priporočenem odmerku 300/100 mg enkrat na dan.
In HIV-infected patients with atazanavir/ritonavir at the recommended dose of 300/100 mg once daily
Pri z virusom HIV okuženih bolnikih, ki so se zdravili z atazanavirjem/ritonavirjem v priporočenem odmerku 300/100 mg enkrat na dan
In HIV-infected patients with mild to moderate hepatic impairment, an increase of approximately 30% in lopinavir exposure has been observed but is not expected to be of clinical relevance (see section 5.2).
Pri s HIV okuženih bolnikih z blago do zmerno jetrno okvaro so opazili za približno 30% večjo izpostavljenost lopinavirju, vendar ni pričakovati, da bi to bilo klinično pomembno (glejte poglavje 5.2).
In HIV-infected patients with severe immune deficiency at the time of initiation of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic infections may arise.
Pri s HIV okuženih bolnikih s hudo imunsko pomanjkljivostjo lahko ob uvedbi kombiniranega protiretrovirusnega zdravljenja (CART – „combination antiretroviral therapy“) nastane vnetna reakcija na asimptomatične ali rezidualne oportunistične okužbe.
In HIV-infected patients with severe immune deficiency at the time of initiation of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic infections may arise.
Pri z virusom HIV okuženih bolnikih s hudo imunsko pomanjkljivostjo lahko ob uvedbi kombiniranega protiretrovirusnega zdravljenja (CART – ''combination antiretroviral therapy'') nastane vnetna reakcija na asimptomatične ali rezidualne oportunistične okužbe.
In HIV-infected patients with severe immune deficiency at the time of institution of combination anti- retroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms.
Pri s HIV okuženih bolnikih s hudo imunsko pomanjkljivostjo lahko ob uvedbi kombiniranega protiretrovirusnega zdravljenja (CART - combination antiretroviral therapy) nastane vnetna reakcija na asimptomatične ali rezidualne oportunistične patogene in povzroči resno klinično stanje ali poslabšanje simptomov.
In HIV-infected patients with severe immune deficiency at the time of institution of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms.
Pri bolnikih, okuženih s HIV, ki imajo v času uvedbe kombinirane protiretrovirusne terapije (CART – combination antiretroviral therapy) hudo imunsko pomanjkljivost, se lahko pojavi vnetna reakcija na asimptomatske ali rezidualne oportunistične patogene ter povzroči resna klinična stanja ali poslabšanje simptomov.
In HIV-infected patients with severe immune deficiency at the time of institution of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms.
Pri s HIV okuženih bolnikih s hudo imunsko pomanjkljivostjo lahko ob uvedbi kombiniranega protiretrovirusnega zdravljenja nastane vnetna reakcija na asimptomatične ali rezidualne oportunistične patogene in povzroči resna klinična stanja ali poslabšanje simptomov.
In HIV-infected patients with severe immune deficiency at the time of institution of combination antiretroviral therapy (CART), an inflammatory reaction to asymtomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms.
Pri z virusom HIV okuženih bolnikih s hudo imunsko pomanjkljivostjo lahko ob uvedbi kombiniranega protiretrovirusnega zdravljenja (CART – ''combination antiretroviral therapy'') nastane vnetna reakcija na asimptomatične ali rezidualne oportunistične patogene in povzroči resna klinična stanja ali poslabšanje simptomov.
In HIV-infected patients,total clearance of stavudine is 594±164 ml/min, and renal clearance is 237±98 ml/min.
Pri z virusom HIV okuženih bolnikih skupni očistek stavudina znaša 594±164 ml/min, ledvični očistek pa 237±98 ml/min.
In HIV–infected paediatric patients, the pharmacokinetic parameters of indinavir in apple sauce were: AUC0–8hr of 26,980 nM*h; peak plasma concentration of 13,711 nM; and plasma concentration at 8 hours post dose of 146 nM.
Pri s HIV okuženih pediatričnih bolnikih so bili farmakokinetični parametri indinavirja v jabolčnem soku naslednji: AUC0-8h 26.980 nM*h, najvišja plazemska koncentracija 13.711 nM, plazemska koncentracija 8 ur po odmerku pa 146 nM.
In HL, Adcetris has been studied in one main study in 102 patients with CD30-positive HL, who had previously received an autologous stem cell transplant and whose cancer had come back or had not responded to previous treatment.
Pri Hodgkinovem limfomu so zdravilo Adcetris proučevali v eni glavni študiji pri 102 bolnikih s Hodgkinovim limfomom, pozitivnim na CD30, ki so predhodno že prejeli zdravljenje z avtologno presaditvijo matičnih celic, vendar se je rak ponovil ali se na prejšnje zdravljenje niso odzvali.
In homocystinuria, betaine reduces homocysteine levels in the blood by facilitating a reaction in the body called ‘methylation’, which converts homocysteine back into methionine.
Pri homocistinuriji betain znižuje raven homocisteina v krvi tako, da v telesu spodbuja reakcijo, imenovano metiliranje, pri kateri se homocistein ponovno pretvarja v metionin.
In homozygous familial hypercholesterolaemia, Repatha was studied in 2 main studies involving 155 patients, which included 14 children older than 12 years.
Zdravilo Repatha so pri zdravljenju homozigotne družinske hiperholesterolemije proučevali v dveh glavnih študijah, ki sta vključevali 155 bolnikov, vključno s 14 otroci, starejšimi od 12 let.
In horses given the granules in sachet and oral suspension, slight urticaria (itchy rash) and diarrhoea were observed in clinical trials.
Pri konjih, ki so jim dajali zrnca iz vrečke in peroralno suspenzijo, so v kliničnih preskušanjih opazili blažjo urtikarijo (srbeč izpuščaj) in drisko.
In horses given the oral paste, isolated cases of slight urticarial (itchy rash) and diarrhoea were observed in clinical trials which were reversible.
Pri konjih, ki so jim dajali peroralno pasto, so v kliničnih preskušanjih opazili osamljene primere blažje urtikarije (srbečega izpuščaja) in driske, ki sta bili prehodne narave.
In horses with RAO, the immune system (the body’s natural defences) over-reacts to triggering substances (antigens) that are present in dust that the horse breathes in.
Pri konjih z RAO imunski sistem (naravna obramba telesa) čezmerno reagira na sprožilce (antigene), prisotne v prahu, ki ga vdihavajo konji.
In horses, a transient swelling at the injection site can occur but resolves without intervention.
Pri konjih se lahko na mestu vboda pojavi prehodna oteklina, ki mine brez posredovanja.
In horses, a transient swelling at the injection site can occur but resolves without intervention.
Pri konjih se lahko pojavi prehodna oteklina na mestu injiciranja, ki uplahne brez intervencije.
In horses, anaphylactoid (allergic) reactions can occur and should be treated according to the signs presented.
Pri konjih se lahko pojavijo anafilaktoidne (alergijske) reakcije, ki jih je treba zdraviti glede na pojav znakov.
In horses, Inflacam is used for the relief of pain associated with colic (abdominal pain) and for the alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders (disorders affecting the muscles and bones).
Pri konjih se zdravilo Inflacam uporablja za lajšanje kolike (trebušnih bolečin) ter vnetja in bolečin pri akutnih in kroničnih kostno-mišičnih obolenjih (obolenjih, ki prizadenejo mišice in kosti).
In horses, Metacam is used for the relief of pain associated with colic (abdominal pain) and for the alleviation of inflammation and relief of pain in both acute and chronic (long-term) musculo-skeletal disorders (disorders affecting the muscles and bones).
Pri konjih se zdravilo Metacam uporablja za lajšanje kolike (trebušnih bolečin) ter vnetja in bolečin pri akutnih in kroničnih (dolgotrajnih) kostno-mišičnih obolenjih.
In horses, Quadrisol 100 mg/ml oral gel is used to relieve pain and reduce inflammation due to problems with and injury to the muscles, bones and joints and also injuries to other non-bony areas of the body(so called soft tissue lesions) including the trauma caused by surgery.
Pri konjih uporabljamo peroralni gel Quadrisol 100 mg/ml za zmanjšanje vnetja in bolečine zaradi težav z mišicami, kostmi in sklepi ter poškodb teh struktur in zaradi poškodb drugih nekostnih delov telesa (t.i. poškodb mehkih tkiv), med drugim zaradi kirurških posegov.
In horses, Rheumocam is used for the relief of pain associated with colic (abdominal pain) and for the alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders (disorders affecting the muscles and bones).
Pri konjih se zdravilo Rheumocam uporablja za lajšanje bolečin, povezanih s kolikami (bolečinami v trebuhu) ter za blažitev vnetja in bolečin pri akutnih in kroničnih kostno-mišičnih obolenjih (obolenjih, ki prizadenejo mišice in kosti).
In horses, skin rashes (urticaria) have been reported.
Pri konjih so opazili kožne izpuščaje (urtikarije).
In horses, transient swellings at the injection site can occur but resolves without intervention.
Pri konjih se lahko na mestu dajanja pojavi prehodna oteklina, ki spontano izgine.
In households of influenza-infected index cases, there was a reduction in the incidence of influenza from 26 % (23 / 89) in the group not receiving prevention to 11 % (9 / 84) in the group receiving prevention (58.5 % reduction [95 % CI 15.6 – 79.6; p = 0.0114]).
V gospodinjstvu s kliničnimi simptomi gripe je bilo znižanje pojavnosti influence iz 26 % (23/89) v skupini, ki ni prejemala zdravila za preprečevanje na 11 % (9/84) v skupini, ki je prejemala zdravilo za preprečevanje (58,5-% znižanje [95-% interval zaupanja 15,6 – 79,6; p = 0,0114]).
In households of influenza-infected index cases, there was a reduction in the incidence of influenza from 26 % (23/89) in the group not receiving prevention to 11 % (9/84) in the group receiving prevention (58.5 % reduction [95 % CI 15.6 – 79.6; p = 0.0114]).
V gospodinjstvu s kliničnimi simptomi gripe je bilo znižanje pojavnosti influence iz 26 % (23/89) v skupini, ki ni prejemala zdravila za preprečevanje, na 11 % (9/84) v skupini, ki je prejemala zdravilo za preprečevanje (58,5-% znižanje 95-% interval zaupanja 15,6–79,6; p = 0,0114).
In human clinical studies, a 10 mg oral dose of tenofovir alafenamide (given with emtricitabine and elvitegravir and cobicistat) resulted in tenofovir diphosphate concentrations > 4-fold higher in PBMCs and > 90% lower concentrations of tenofovir in plasma as compared to a 245 mg oral dose of tenofovir disoproxil (as fumarate) (given with emtricitabine and elvitegravir and cobicistat).
V kliničnih študijah pri ljudeh je 10 mg peroralni odmerek alafenamidtenofovirata (v kombinaciji z emtricitabinom in elvitegravirjem in kobicistatom) v PBMC povzročil > 4-krat višje koncentracije tenofovir difosfata in > 90 % nižje koncentracije tenofovirja v plazmi v primerjavi z 245 mg peroralnim odmerkom dizoproksiltenofovirata (v obliki fumarata) (v kombinaciji z emtricitabinom in elvitegravirjem in kobicistatom).
In human clinical studies, a 10 mg oral dose of tenofovir alafenamide given with emtricitabine, cobicistat and elvitegravir resulted in tenofovir diphosphate concentrations > 4-fold higher in PBMCs and > 90% lower concentrations of tenofovir in plasma as compared to a 245 mg oral dose of tenofovir disoproxil (as fumarate) given with emtricitabine, cobicistat and elvitegravir.
V kliničnih študijah pri ljudeh je 10 mg peroralni odmerek alafenamidtenofovirata v kombinaciji z emtricitabinom, kobicistatom in elvitegravirjem v PBMC povzročil > 4-krat višje koncentracije tenofovir difosfata in > 90 % nižje koncentracije tenofovirja v plazmi v primerjavi z 245 mg peroralnim odmerkom dizoproksiltenofovirata (v obliki fumarata) v kombinaciji z emtricitabinom, kobicistatom in elvitegravirjem.
In human clinical studies, a 10 mg oral dose of tenofovir alafenamide in Genvoya resulted in tenofovir diphosphate concentrations > 4-fold higher in PBMCs and > 90% lower concentrations of tenofovir in plasma as compared to a 245 mg oral dose of tenofovir disoproxil (as fumarate) in E/C/F/TDF.
V kliničnih študijah pri ljudeh je 10 mg peroralni odmerek alafenamidtenofovirata v zdravilu Genvoya v PBMC povzročil > 4-krat višje koncentracije tenofovir difosfata in > 90 % nižje koncentracije tenofovirja v plazmi v primerjavi z 245 mg peroralnim odmerkom dizoproksiltenofovirata (v obliki fumarata) v E/C/F/TDF.
In human lymphocyte cultures in-vitro clastogenic effects of achromatic, chromatid, isochromatic breaks or chromatid translocations were not seen at 153 or 600 µg /mL but at 1500 and 3000 µg /mL there was a dose related increase in chromatid aberrations.
Na kulturah človeških limfocitov in vitro pri 153 in 600 µg/ml niso opazili klastogenih učinkov v smislu akromatskih, kromatidnih in izokromatskih zlomov ali translokacij kromatid, pri 1500 in 3000 µg/ml pa so opazili z odmerkom povezano povečanje števila kromatidnih aberacij.
In human subjects, hepatic enzyme induction by phenobarbital has led to an increase in total plasma clearance (approximately 25%) following intravenous administration of granisetron.
Pri človeških preiskovancih je spodbujanje jetrnih encimov s fenobarbitalom po intravenskem dajanju granisetrona povzročilo zvečanje celotnega plazemskega očistka (približno za 25 %).
In human volunteers, a dose-dependent decrease in prolactin was observed.
Pri prostovoljcih so opazili od odmerka odvisno zmanjšane vrednosti prolaktina.
In human washed blood cells also evidence of hemolysis was found with non-commercial formulations at fosaprepitant concentrations of 2.3 mg/ml and higher, although tests in human whole blood were negative.
Izprane humane krvne celice so pri preskusih nekomercialnih oblik fosaprepitanta pri koncentracijah fosaprepitanta 2,3 mg/ml in večjih kazale znake hemolize, preiskave polne krvi pa so bile negativne.
In human, an 80 mg dose of telmisartan almost completely inhibits the angiotensin II evoked blood pressure increase.
Pri človeku odmerek telmisartana 80 mg skoraj povsem zavre povečanjekrvnega tlaka, ki ga povzroča angiotenzin II.
In humans, less than 1% to 5% of the dose was recovered as parent drug in faeces and urine respectively after 2 weeks of collection indicating that oritavancin is slowly excreted unchanged.
Pri ljudeh so po 2 tednih zbiranja prestregli manj kot 1 % izhodiščne učinkovine v blatu in manj kot 5 % v urinu, kar kaže, da se oritavancin počasi izloča v nespremenjeni obliki.
In humans, nicotinamide is further predominantly metabolised to
Pri človeku se nikotinamid nato presnovi v glavnem v N-metilnikotinamid (MNA) in